Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be
removed.
PURPOSE: This phase II trial is studying how well gefitinib works in treating patients who
are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer.
Phase:
N/A
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute